Stockwinners Market Radar for August 28, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EDT Hutchmed receives breakthrough therapy designation in China for Savolitinib - Hutchmed announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to savolitinib for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies.

19:12 EDT User reports indicate problems at T-Mobile, Downdetector says - Reference Link

17:30 EDT TSR trading resumes

17:20 EDT Jackson Financial to replace NexTier Oilfield in S&P 600 at open on 9/1 - Jackson Financial (JXN) will replace NexTier Oilfield Solutions (NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy (PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final conditions.

17:01 EDT TSR to explore strategic alternatives - TSR, Inc. announced that its Board of Directors has initiated a process to identify and evaluate potential strategic alternatives to maximize shareholder value. The company expects to consider a range of options, which may include a sale of or acquisitions by the company or a special dividend, as well as other potential alternatives. The company has retained Focus Investment Banking, LLC as its financial advisor and Shulman Rogers as its legal advisor to assist the Board in the evaluation process. Brad Tirpak, Chairman of TSR, said, "Over the last few years, TSR's management and employees have orchestrated a phenomenal turn-around by providing best in class service to our existing and new customers. While transitioning from an enterprise generating losses to a solidly profitable company, TSRI has also built up a solid cash position and has an unused line of credit. We feel that TSR's current stock price does not fairly represent the true value of the Company. That's why we believe the best way to continue to maximize shareholder value is to explore our options, while remaining intensely committed to the satisfaction of our customers and employees."

16:55 EDT TSR trading halted, news pending

16:48 EDT Timken EVP Coughlin sells 10,000 common shares - In a regulatory filing, Timken executive VP Christopher Coughlin disclosed the sale of 10,000 common shares of the company on August 25 at a price of $75.05 per share.

16:42 EDT Bright Horizons CEO Kramer sells 15,000 common shares - In a regulatory filing, Bright Horizons president and CEO Stephen Howard Kramer disclosed the sale of 15,000 common shares of the company on August 25 at a price of $95.6492 per share.

16:32 EDT CalAmp CEO Jeff Gardner passes away, Jason Cohenour named interim CEO - CalAmp announced that Jeff Gardner, the company's president and CEO, passed away unexpectedly on August 27 due to presumed natural causes. Henry Maier, chairman of the board of directors, issued the following statement on behalf of the Board: "We are shocked and profoundly saddened by the passing of Jeff Gardner. Jeff was a dedicated and humble leader who cared deeply for his colleagues, his family and his community. We extend our most heartfelt condolences and sympathy to his family, especially his wife, Chris, and their three boys. We will honor his legacy and remember the extraordinary impact he had on so many. Our thoughts and prayers are with them during this difficult time." Jason Cohenour, director on CalAmp's board of directors, has been named Interim CEO by the board, effective immediately.

16:27 EDT Daxor reports net assets were $30,359,013 or $6.33 p/s as of June 30 - As of June 30 Daxor's net assets were $30,359,013 or $6.33 per share as compared to $28,969,469, or $6.75 per share on December 31, 2022. This increase in net assets is primarily due to the public offering during the six-month period ended June 30 , whereby Daxor raised $4.1M net to Daxor by selling 464,599 shares at $9.75. The net asset value per share was adjusted to account for the addition of 464,599 shares to the float of the stock. For the six-month period ended June 30 Daxor had net dividend income of $77,990, and net realized gains on investment activity of $603,661. Focusing further on the operating division financial performance, the Company is pleased to report a 20.64% increase in the unaudited revenues of our single-use test kits for the six-month period ended June 30, as compared to the six-month period ended June 30, 2022. Revenue growth was driven by a combination of the sale and leasing of our capital equipment to hospitals and orders for our single-use blood volume diagnostics kits for heart failure management, critical care use, among other indications... In June of this year Daxor launched its new ezBVA Lab service for clinical sites that wish to perform BVA testing using Daxor's lab services without the need for an on-site analyzer. This new service, priced at $965 per test, represents a significant value for customers and is a premium to the sale of a test kit which sells for $385.

16:17 EDT LianBio announces data from phase 3 EXPLORER-CN trial of Mavacamten - LianBio announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese symptomatic obstructive hypertrophic cardiomyopathy, oHCM, patients were presented in a late-breaking science session at the European Society of Cardiology ,ESC, Congress 2023 and simultaneously published in a JAMA Cardiology paper titled, "Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy." LianBio previously announced topline data from EXPLORER-CN, with mavacamten demonstrating statistically significant and clinically meaningful improvement in Valsalva left ventricular outflow tract , LVOT, peak gradient, the study's primary endpoint. Mavacamten also demonstrated improvement across all secondary endpoints, including LVOT obstruction, clinical symptoms, and health status. The data presented at ESC 2023 and published in JAMA Cardiology continue to demonstrate robust evidence of mavacamten's therapeutic benefit. New data published today provide additional detail showing mavacamten's impact on reducing cardiac biomarkers associated with poor prognosis in oHCM, and improvement in biomarkers associated with cardiac structure remodeling. In addition, the study demonstrated mavacamten's efficacy across prespecified subgroups, including beta-blocker usage, sex, age, body mass index, New York Heart Association NYHA class, and CYP2C19 metabolizer phenotype.

16:08 EDT LifeVantage announces 40c per share special dividend - LifeVantage announced that the company's board of directors has declared a special one-time cash dividend of 40c per share of common stock, which will be paid September 22 to all stockholders of record at the close of business on September 8.

16:06 EDT Installed Building Products acquires Interior 2000 Products, terms not disclosed - Installed Building Products announced the acquisition of Interior 2000 Products, LLC. Established in 1999, Interior 2000 installs shower, shelving, and mirror products, as well as fireplaces into new and existing residential and commercial construction projects throughout the greater Richmond, Virginia market. On August 6, IBP completed the acquisition of R-Pro Select, LLC, a Fletcher, North Carolina based installer of fiberglass, spray foam, cellulose insulation, and fireplaces to residential customers primarily in Asheville, Hendersonville, and the surrounding communities of western North Carolina. "Interior 2000 increases our footprint throughout the greater Richmond market with nearly $6 million of annual revenue and complements our existing residential insulation installation branch," stated Jeff Edwards, Chairman and Chief Executive Officer. "In addition, our recent acquisition of R-Pro increases our presence within the western North Carolina region. To date in 2023, we have acquired over $55 million of annual revenue. Acquisitions remain a key component of our growth strategy and we continue to have a robust pipeline of opportunities across multiple geographies, products, and end markets. On behalf of everyone at Installed Building Products, I want to welcome Interior 2000 and R-Pro onto our team."

16:03 EDT Peoples Bancorp announces two executive appointments - Peoples Bancorp announced the election of Hugh Donlon to the position of executive VP, Community Banking, effective September 5, and the election of Matthew Macia to the position of executive VP, Chief Risk Officer, effective August 21. The positions are with Peoples and its banking subsidiary, Peoples Bank. Donlon succeeds Tyler Wilcox, who was elevated to senior executive VP, COO, of Peoples and Peoples Bank on July 11.

14:57 EDT Regeneron treatment of myasthenia gravis granted FDA orphan status - Regeneron's pozelimab and cemdisiran combination was granted FDA orphan status as a treatment of myasthenia gravis, according to a post to the agency's website. Reference Link

14:45 EDT First Light Acquisition Group Inc trading resumes

14:35 EDT First Light Acquisition Group Inc trading halted, volatility trading pause

12:49 EDT Polaris unveils two new electric boats with Forza X1 motors - Polaris Marine (PII) unveiled two new concept electric pontoons under its Bennington and Godfrey Pontoons brands. The concept vessels were built on the 26-foot, 6-inch 2024 Bennington L-Series Bowrider and the 23-foot, 11-inch 2023 Godfrey Monaco 235 platforms. The company said, "With a 150-hp outboard electric motor from Forza X1, the Bennington and Godfrey demonstrators reached a top speed of 25 mph and 28 mph, respectively. With this power, the cruising range of the Bennington was gauged comfortably to be 25 miles at 15 mph or 15 miles at 20 mph, while the Godfrey clocked in at 15 mph for an estimated range of 29 miles or 20 mph for 17 miles. The systems were controlled by a custom interface, Garmin touch screen display, and equipped with 4G connectivity for monitoring the system remotely via an app." Forza X1 (FRZA) said via Twitter, "We're thrilled to announce our partnership with @PolarisInc, bringing electrifying innovation to two renowned pontoon boat brands: @GodfreyPontoons and @BennyPontoons."

12:45 EDT Forza X1 announces electric pontoon partnership with Polaris

12:22 EDT SEC charges Impact Theory over unregistered NFT 'securities' - The Securities and Exchange Commission charged Impact Theory, a media and entertainment company headquartered in Los Angeles, with conducting an unregistered offering of crypto asset securities in the form of purported non-fungible tokens. Impact Theory raised approximately $30M from hundreds of investors, including investors across the United States, through the offering. According to the SEC's order, from October to December 2021, Impact Theory offered and sold three tiers of NFTs, known as Founder's Keys, which Impact Theory called "Legendary," "Heroic," and "Relentless." The order finds that Impact Theory encouraged potential investors to view the purchase of a Founder's Key as an investment into the business, stating that investors would profit from their purchases if Impact Theory was successful in its efforts. Among other things, Impact Theory emphasized that it was "trying to build the next Disney," and, if successful, it would deliver "tremendous value" to Founder's Key purchasers. The order finds that the NFTs offered and sold to investors were investment contracts and therefore securities. Accordingly, Impact Theory violated the federal securities laws by offering and selling these crypto asset securities to the public in an unregistered offering that was not otherwise exempt from registration. Without admitting or denying the SEC's findings, Impact Theory agreed to a cease-and-desist order finding that it violated registration provisions of the Securities Act of 1933 and ordering it to pay a combined total of more than $6.1M in disgorgement, prejudgment interest, and a civil penalty. The order also establishes a Fair Fund to return monies that injured investors paid to purchase the NFTs. Impact Theory agreed to destroy all Founder's Keys in its possession or control, publish notice of the order on its websites and social media channels, and eliminate any royalty that Impact Theory might otherwise receive from future secondary market transactions involving the Founder's Keys. Reference Link

12:08 EDT WWE announces John Cena's return to 'Friday Night SmackDown' - WWE announced that John Cena, who returns to Friday Night SmackDown this Friday, September 1 at The Giant Center in Hershey, Pa., will also appear on Friday Night SmackDown for seven consecutive weeks beginning Friday, September 15 at Ball Arena in Denver through the end of October. As previously announced, Cena will appear at the WWE Superstar Spectacle at GMC Balayogi Indoor Stadium in India on Friday, September 8.

12:05 EDT FirstEnergy restores power to over 97% of customers impacted by OH, PA outages - FirstEnergy utilities have restored power to more than 97% of the 466,000 customers impacted by power outages in Ohio and Pennsylvania following last week's storms. As of this morning, approximately 12,000 customers remain without service, particularly in the hardest hit areas in eastern Cuyahoga County, western Lake County, central Geauga County and central Portage County in Ohio. FirstEnergy employees, contractors and outside resources will continue working around the clock until power has been restored for all customers.

12:00 EDT Ampco-Pittsburgh falls -7.6% - Ampco-Pittsburgh is down -7.6%, or -27c to $3.26.

12:00 EDT RPT Realty rises 18.3% - RPT Realty is up 18.3%, or $1.75 to $11.32.

12:00 EDT Hersha Hospitality rises 56.3% - Hersha Hospitality is up 56.3%, or $3.54 to $9.81.

11:29 EDT Bristol Myers announces long-term follow-up data from Phase 3 studies of CAMZYOS - Bristol Myers Squibb announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS, a cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy. Results from the 56-week analysis of the VALOR-HCM long-term extension study were presented as a late-breaking oral presentation, with simultaneous publication in JAMA Cardiology, and results from the cumulative 120-week analysis of the EXPLORER cohort of the MAVA-LTE study were presented as an oral presentation at the European Society of Cardiology Congress 2023. Key findings from the 56-week analysis of VALOR-HCM LTE include: Treatment with CAMZYOS demonstrated sustained improvements across key study endpoints in both the original CAMZYOS group over 56 weeks and those transitioned to the placebo cross-over group over 40 weeks. At Week 56, 5 of 56 patients in the original CAMZYOS group and 10 of 52 patients in the placebo cross-over group at Week 40 decided to proceed with septal reduction therapy or were SRT-eligible. CAMZYOS demonstrated sustained reduction in peak resting LVOT gradient. Proportion with NYHA class improvement of greater than or equal to1 class was observed in 93% of patients in the original CAMZYOS group at Week 56 and 73% of patients from the placebo cross-over group at Week 40. On the patient-reported 23-item Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, average scores of symptom frequency, symptom burden and physical limitation continued to improve with a 14.1 point increase for the original CAMZYOS group and 11.7 point increase for the placebo crossover group. CAMZYOS was also associated with sustained reduction across biomarkers of cardiac wall stress and myocardial injury including reduction in N-terminal pro brain natriuretic peptide, with -376 ng/L for the original CAMZYOS group and -423 ng/L for the placebo cross-over group and reduction in cardiac troponin I with -7.0 ng/L for the original CAMZYOS group and -6.2 ng/L for the placebo cross-over group. No new safety signals were observed, and safety and efficacy were consistent across both patient groups. The KCCQ-23 CSS is derived from the Total Symptom Score and the Physical Limitations score of the KCCQ-23. The CSS ranges from 0 to 100 with higher scores representing better health status. Key findings from the cumulative 120-week analysis of EXPLORER-LTE include: No new safety signals were observed. Overall, 75.9% of patients improved by greater than or equal to1 NYHA class from baseline at the start of the LTE study to Week 120. Of the 14 patients who were in NYHA class I, 12 remained in NYHA class I at the latest available assessment. Treatment with CAMZYOS was associated with sustained improvements from baseline at the start of the LTE study in echocardiographic parameters, including E/e' average and NT-proBNP. Mean LVEF remained within the normal range at all study visits. Since the previous interim analysis in August 2021, one new patient experienced a transient reduction in LVEF less than50% resulting in temporary treatment interruption.

11:21 EDT UTime to change Nasdaq ticker symbol to 'WTO' - UTime Limited (UTME) announced that the company will be changing its ticker symbol from "UTME" to "WTO". Effective on Tuesday September 5, the company's ordinary shares will trade on Nasdaq under the new symbol "WTO". "No action is required by existing shareholders with respect to the ticker symbol change. The company's ordinary shares will continue to be listed on Nasdaq and the CUSIP will remain unchanged," the company stated. "According to the needs of the company's future strategy and business development, we will officially change the ticker symbol. Over the past few years, the company has actively sought to diversify its business development and has brought us new business growth opportunities in many areas. The change of the company's ticker symbol to 'WTO' will have a positive impact on building the company's long-term brand influence and enhancing our brand value," CEO Hengcong Qiu added.

11:05 EDT CYBN Stock trading resumes

11:02 EDT Carvana announces passage of legislation in Illinois for vehicle home delivery - Carvana announced the conclusion to its campaign to enact legislation that more formally allows car buyers in the state the convenience of home delivery. Legislation sponsored by Illinois State Sen. Patrick Joyce and supported by thousands of Illinois consumers, explicitly permitting vehicle home delivery passed the Illinois Senate unanimously by a 57-0 vote, the Illinois House of Representatives by a 113 - 0 margin, and was signed into law by Illinois Governor JB Pritzker. The legislation modernizes existing vehicle sales laws, which were over 50 years old and did not formally account for current conveniences, like home delivery, that are now afforded to vehicle buyers in the state.

10:52 EDT Cybin to acquire Small Pharma in all-share transaction - Cybin (CYBN) and Small Pharma (DMTTF) have entered into a definitive arrangement agreement pursuant to which Cybin will acquire all of Small Pharma's issued and outstanding securities in an all-share transaction pursuant to a plan of arrangement. Under the terms of the Transaction, Small Pharma shareholders will receive 0.2409 common shares in the capital of Cybin for each common share of Small Pharma held. The exchange ratio implies consideration of approximately C$0.10 per Small Pharma Share based on the closing price of the Cybin Shares on the Cboe Canada exchange on August 25, 2023, representing a 43.64% premium based on the 30-day volume weighted average prices of the Cybin Shares on the Cboe Canada and the Small Pharma Shares on the TSX Venture Exchange for the period ended on August 25, 2023. As of the date of this press release, it is expected that existing Cybin shareholders and Small Pharma securityholders will own approximately 74.5% and 25.5% of Cybin, respectively. The Agreement has been unanimously approved by Small Pharma's board of directors on the unanimous recommendation of a special committee of its independent directors and Cybin's board of directors. The company said, "Small Pharma is a leader in the development of short-duration psychedelic therapies for mental health conditions, having raised a total of $63 million in capital since 2021, and demonstrating the first placebo-controlled efficacy results for N,N-dimethyltryptamine in treating Major Depressive Disorder. In the past years Small Pharma has progressed two clinical-stage DMT-based programs, a pipeline of preclinical assets, and developed a highly robust intellectual property portfolio to protect them. With a common goal to create novel, optimized psychedelic-based therapeutics, the combination of Cybin and Small Pharma creates an international, clinical-stage leader with the potential to transform the treatment paradigm for mental health conditions. Cybin's and Small Pharma's combined DMT and deuterated DMT programs creates the largest dataset of systematic research on these short-duration psychedelic molecules. The companies' combined development portfolios are highly complementary and provide multiple opportunities to create operational and cost synergies. The combined entity will hold the most impressive IP portfolio in the psychedelic drug development sector, with a combined 158 pending patent applications, including two allowed applications, and 28 granted patents protecting the combined companies' clinical and preclinical molecules. This extensive IP portfolio creates an unmatched opportunity for the combined company to develop next-generation novel compounds for a number of mental health disorders that may be amenable to treatment with psychedelic therapies." The combined company will be led by Cybin's Chief Executive Officer, Doug Drysdale. Small Pharma senior management and staff will be integrated with the existing Cybin team to create a highly experienced and skilled team. Pursuant to the Transaction, Small Pharma shareholders will receive 0.2409 Cybin Shares for each Small Pharma Share held. Holders of options to purchase Small Pharma Shares that are "in-the-money" based on the volume weighted average trading price of the Small Pharma Shares on the TSXV for the five trading days immediately preceding the effective time of the Transaction will receive from Small Pharma a number of Small Pharma Shares equal to the number of Small Pharma options held, multiplied by the amount by which the Small Pharma Share Value exceeds the exercise price of such Small Pharma options, divided by the Small Pharma Share Value. Such newly issued Small Pharma Shares will be acquired by Cybin on the same terms as the other Small Pharma Shares. Each Small Pharma option that is "out-of-the-money" based on the Small Pharma Share Value will be deemed to be surrendered to Small Pharma for $0.001 and cancelled. The Transaction will be effected by way of a court-approved plan of arrangement under the Business Corporations Act, requiring the approval of at least 662/3% of the votes cast by the shareholders of Small Pharma voting in person, virtually or by proxy at an annual and special shareholders' meeting to consider, in addition to certain annual business, the Transaction. The issuance of Cybin Shares pursuant to the Transaction will also require approval by a simple majority of the votes cast by the shareholders of Cybin voting virtually or by proxy at an annual and special meeting of Cybin shareholders, in accordance with the polices of the Cboe Canada. The shareholders' meetings are expected to occur on or about October 12, 2023. In addition to shareholder approvals, the Transaction is subject to approval by the Supreme Court of British Columbia, receipt of applicable stock exchange and regulatory approvals, including the approval of the TSXV, and the satisfaction of certain other closing conditions customary in transactions of this nature. It is currently expected that the Transaction will close in late October 2023. The Agreement includes customary reciprocal "non-solicitation" covenants, subject in the case of "fiduciary out" provisions that would permit Small Pharma to accept a superior proposal under certain circumstances, subject to a "right to match" period in favour of Cybin. The Agreement also provides for reciprocal termination fees of $2 million payable to Cybin or Small Pharma if the Transaction is terminated in certain specified circumstances, and, in certain other customary circumstances, expense reimbursement payable to Small Pharma of $400,000. Upon completion of the Transaction, the Cybin Board will be increased by one director, and George Tziras, the current Chief Executive Officer of Small Pharma, will join the Cybin Board.

10:23 EDT DoorDash launches AI-powered voice ordering capabilities - DoorDash announced its development of voice ordering capabilities incorporating AI, building on its existing model leveraging agents, to further support restaurant operations. The company said, "The cost-efficient innovation will enable select operators the potential to increase their sales by answering all calls and pursuing incremental revenue opportunities, while providing an excellent end-to-end customer experience....According to our newly-released 2023 Restaurant Online Ordering Trends Report, one in five customers prefer to order takeout via phone - and according to qualitative DoorDash research, this preference stems from wanting convenience, customization, and familiarity. Despite the preference, with continued staffing issues, fluctuations in customer demand, and an emphasis on in-store hospitality, operators may be leaving revenue on the line. DoorDash listened to feedback from restaurant partners and customer preferences to incorporate AI into our voice ordering product that could further increase the variable profits of operator's businesses without sacrificing quality." Reference Link

10:01 EDT Vahanna Tech Edge Acquisition I Corp trading resumes

10:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -4.4% - ProShares UltraShort Bloomberg Natural Gas is down -4.4%, or -$2.42 to $52.06.

10:00 EDT RPT Realty rises 18.5% - RPT Realty is up 18.5%, or $1.77 to $11.34.

10:00 EDT Hersha Hospitality rises 56.8% - Hersha Hospitality is up 56.8%, or $3.57 to $9.85.

09:49 EDT Verses AI completes Flying Forward 2020 program - VERSES AI announced the completion of Flying Forward 2020. The three-year project that began in November 2020 was funded by the European Union to test the viability of autonomous drones across five European cities. The final two trial cities, Oulu, Finland and Tartu, Estonia, join the three other sites - Eindhoven, Netherlands, Milan, Italy, and Zaragoza, Spain - in demonstrating essential digital infrastructure for governing autonomous drones. VERSES platform, KOSM, was deployed in Oulu to map navigation routes and landing zones in urban areas based on 5G/6G signal strength as well as inspect locations such as winter roads and parking spaces while in Tartu, KOSM was implemented for preventative maintenance by automatically monitoring solar panels.The FF2020 consortium includes 12 global partners, working in concert to define a governance model, a regulatory framework, a geospatial digital infrastructure, a Digital Toolbox, an Identity of Things scheme and interoperability frameworks for autonomous drones. These deliverables were identified in the scope of the program as foundational to enabling a vast array of unmanned drone use cases including emergency response, surveillance, last mile delivery and taxi drones which collectively represent significant commercial value in efficiency, effectiveness and safety.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -4.9% - ProShares UltraShort Bloomberg Natural Gas is down -4.9%, or -$2.64 to $51.84.

09:47 EDT Universal Insurance falls -6.3% - Universal Insurance is down -6.3%, or -81c to $12.04.

09:47 EDT Hawaiian Electric rises 37.8% - Hawaiian Electric is up 37.8%, or $3.65 to $13.31.

09:41 EDT Hawaiian Electric trading resumes

09:37 EDT Overseas Shipholding to purchase 3.79M shares from Cyrus for $4.05 per share - Overseas Shipholding announced that it has agreed to purchase 3,788,639 shares of the company's common stock from entities managed by Cyrus Capital Partners at a price of $4.05 per share for a total consideration of $15,343,987.95 in a privately negotiated transaction. The purchase is expected to be completed today and will be paid out of OSG's available cash. The closing price of OSG common stock in composite trading on August 25, 2023 was $4.01. The purchase is not part of the previously announced program to purchase up to $20M of OSG common stock.

09:33 EDT Mullen Automotive announces Class 3 vehicle purchase order with NRTC - Mullen Automotive announces a multiunit vehicle purchase order with NRTC Automation Group to initially purchase three all-electric commercial Class 3 Mullen trucks with vehicle deliveries slated to begin in Q4 2023.

09:22 EDT CYBN Stock trading halted, news pending

09:10 EDT Dollar Tree names Jonathan Leiken Chief Legal Officer, and Secretary - Dollar Tree (DLTR) announced an addition to its executive leadership team, with Jonathan Leiken joining the organization as Executive Vice President, Chief Legal Officer and Secretary. Leiken has more than 20 years of legal experience, and he most recently served as Executive Vice President, Chief Legal Officer and Secretary of Diebold Nixdorf (DBD). Prior to that, Mr. Leiken was a partner at global law firm Jones Day and an Assistant United States Attorney in the United States Department of Justice, U.S. Attorney's Office for the Southern District of New York .

09:08 EDT Hawaiian Electric up 38% in pre-market trading following update on Maui fire - Shares of Hawaiian Electric are up 38% or $3.55 at $13.25 in pre-market trading following the company's statement on Lahaina fires in response to the lawsuit filed by the County of Maui. The company provided additional details related to the lawsuit stating: "The records conclusively establish that Hawaiian Electric power lines to Lahaina were not energized when the Afternoon Fire broke out shortly before 3 p.m. on Aug. 8, in a field near Lahaina Intermediate School. Power had been out for more than six hours by that time. There was no electricity flowing through the wires in the area or anywhere else on the West Maui coast. Hawaiian Electric has informed ATF investigators of the availability of records that demonstrate these facts. The small Morning Fire, seen in videos taken by local residents, began more than eight hours earlier. Those videos show that power lines had fallen to the ground in high winds near the intersection of Lahainaluna Road and Hookahua Street at approximately 6:30 a.m. A small fire that can be seen by the downed lines spread into the field across the street from the Intermediate School." Hawaiian Electric CEO Shelee Kimura also said: "We were surprised and disappointed that the County of Maui rushed to court even before completing its own investigation. We believe the complaint is factually and legally irresponsible. It is inconsistent with the path that we believe we should pursue as a resilient community committed and accountable to each other as well as to Hawaii's future. We continue to stand ready to work to that end with our communities and others. Unfortunately, the county's lawsuit may leave us no choice in the legal system but to show its responsibility for what happened that day."

09:07 EDT Maris-Tech to exhibit video streaming technologies at Commercial UAV Expo - Maris-Tech announced its participation in the upcoming Commercial UAV Expo in Las Vegas, Nevada, at booth 941. The Company will be demonstrating its flagship products, including the innovative Jupiter family and other ruggedized solutions for drone platforms.

09:05 EDT Google Cloud announces new collaboration with CAPCOM - Google Cloud (GOOG;GOOGL) announced a new collaboration with CAPCOM (CCOEY) in which the game developer, publisher, and distributor is leveraging Google Cloud's secure and scalable infrastructure to deliver performant and secure game launches around the globe. The long-term success of a live service game is often determined by the success of its launch. With Google Cloud, CAPCOM is able to handle live game workloads at planet-scale while ensuring that gameplay is always consistent and reliable around the world.

09:04 EDT Vahanna Tech's shareholders approve business combination with Roadzen - Vahanna Tech Edge Acquisition I and Roadzen, a global insurance technology company, announced that their previously announced business combination was approved at a special meeting of shareholders of Vahanna on August 25. Approximately 83% of the votes cast at the Special Meeting were in favor of the Business Combination. Subject to the satisfaction of customary closing conditions, the transaction is expected to close in September 2023. The combined company will be renamed Roadzen, and its shares and warrants are expected to begin trading on Nasdaq under the symbols "RDZN" and "RDZNW", respectively, one day following the closing date.

09:02 EDT Fortinet announces enhancements to FortiSASE solution - Fortinet announced new enhancements to its single-vendor SASE offering. What's New? SASE for microbranches and IoT/OT devices: FortiSASE now includes expanded integrations within the Fortinet WLAN portfolio to further support organizations securing microbranches and related devices. FortiAP wireless access points intelligently offload traffic from microbranches to a SASE point of presence for comprehensive security inspection at scale for all devices, including IoT and OT devices. This integration also means the Fortinet WLAN portfolio can be managed by the same simple, cloud-based management console customers already use for FortiSASE. All of these updates complement Fortinet's existing support for users at the location and present organizations with a new approach to cloud-based security by extending enterprise-grade protections, such as sandboxing, intrusion prevention system, and URL filtering, to microbranches without additional appliances or services. Enhanced data loss prevention service: As a part of its cloud-delivered security services, FortiSASE includes the FortiGuard powered DLP service to protect sensitive data across the entire hybrid environment. This service now includes a wider range of data identifiers, file types, and Software-as-a-Service applications, as well as advanced data matching techniques to prevent inadvertent data leaks. By continuously enhancing DLP, Fortinet provides organizations with deep insights into their cloud applications and tools to effectively counter new threats. End-to-end digital experience monitoring: Fortinet's DEM offering integrates with FortiSASE to provide insights across users, Fortinet global SASE POPs, and the performance of SaaS applications, including WebEx, Office365, and Dropbox, for comprehensive network and SaaS application monitoring. Additionally, this integration offers endpoint monitoring to deliver end-to-end visibility that empowers IT teams with the information they need to reduce resolution times and ensure a positive user experience.

09:01 EDT QuickLogic enters strategic partnership with YorChip for FPGA chiplets - QuickLogic and YorChip have formed a strategic partnership to revolutionize the world of FPGA chiplets. The collaboration will result in a lineup of FPGA chiplets optimized for low power consumption and low cost, opening new possibilities for a wide range of applications, including the fast-growing edge IoT and AI/ML markets. The partnership leverages QuickLogic's eFPGA IP technology to create the first UCIe-compatible FPGA chiplet ecosystem. This ecosystem will enable customers to connect any UCIe-compatible third-party chiplet, such as a CPU or AI/ML chip, to create a customized system. The ecosystem is also suitable for interoperability testing and joint promotion. "Our partnership with QuickLogic is a giant leap for FPGA technology. Together, we're delivering a groundbreaking lineup of low-power, cost-effective FPGA chiplets that will revolutionize the way designers design and build systems," said Kash Johal, Founder at YorChip.

08:56 EDT AbbVie submits regulatory applications to FDA, EMA for risankizumab - AbbVie announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration, FDA, and European Medicines Agency, EMA, for risankizumab for the treatment of adult patients with moderately to severely active ulcerative colitis. "While there has been advancement in therapies to treat ulcerative colitis, there is still an ongoing need for additional treatments to help those seeking relief from its disruptive effects," said Roopal Thakkar, M.D., senior vice president, development, regulatory affairs and chief medical officer, AbbVie. "These submissions demonstrate our continued commitment to helping people living with IBD, and we look forward to providing a potential new treatment option for the management of ulcerative colitis." Applications to the FDA and EMA are supported by data from two Phase 3 clinical trials: an induction study, INSPIRE, and a maintenance study, COMMAND.1,2 Significantly more patients treated with risankizumab 1200 mg IV at week 12 in the induction study and 180 mg or 360 mg SC at week 52 in the maintenance study achieved the primary endpoint of clinical remission, compared to patients receiving placebo. Additionally, more risankizumab-treated patients in both the induction and maintenance studies achieved the key secondary endpoints of endoscopic improvement and histologic endoscopic mucosal improvement compared to placebo.1,2

08:51 EDT Network-1 Technologies issued eSIM patent from USPTO - Network-1 Technologies announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,736,283, Key Derivation for a Module Using an Embedded Universal Integrated Circuit Card. The newly issued patent is part of comprehensive family of patents that relates to, among other things, the enabling technology for authenticating and using embedded SIM cards in next generation IoT, Machine-to-Machine, and other mobile devices, including smartphones, tablets, and computers as well as automobiles. eSIMs replace the traditional SIM card with internal circuitry that can be remotely provisioned with one or more profiles to access wireless networks. A recent study by the Trusted Connectivity Alliance found that consumer profile downloads to smartphones, watches, tablets, automobiles, and other similar devices increased by more than 130% in 2022. Similarly, industrial machine-to-machine implementations for meters, sensors, automobiles, tracking devices and similar devices grew by 145%. According to TCA, total eSIM enabled device shipments during 2022 approximated 427 million units. Other patents in the portfolio relate to enabling technologies for 5G network authentication used in consumer and M2M devices, and the latest available Internet transport layer security solutions. Network-1's M2M/IoT Patent Portfolio now includes thirty-six issued U.S. patents, plus fourteen issued non-U.S. patents. The patent terms of the MTM/IoT Patent Portfolio are currently expected to extend until 2033-2034. Network-1 anticipates further issuances of additional claims for the M2M/IoT Patent Portfolio.

08:48 EDT LPL Financial supports launch of Revel Private Wealth - LPL Financial announced that financial advisors Megan Stirrat, CFP, CDFA, SE-AWMA and Tenley Hardt have joined LPL Financial to launch a new independent practice, Revel Private Wealth. They chose to affiliate with LPL's supported independence model, LPL Strategic Wealth Services, and reported having served approximately $325M in advisory, brokerage and retirement plan assets. They join LPL from Merrill Lynch.

08:45 EDT Dolby unveils Dolby Atmos FlexConnect - Dolby Laboratories unveiled its latest innovation in immersive audio - Dolby Atmos FlexConnect. TCL, a world leading TV brand, will be the first to implement Dolby Atmos FlexConnect in its 2024 TV lineup. Dolby Atmos FlexConnect is a new feature that seamlessly pairs together a TV's sound system with accessory wireless speakers to unlock a more extensive and immersive Dolby Atmos sound experience. It then intelligently optimizes the sound for any room layout and speaker setup, transforming any seat into the best seat in the house. TCL will also launch a line of accessory wireless speakers designed to complement its upcoming lineup of TVs with Dolby Atmos FlexConnect.

08:41 EDT Array Technologies reports highest U.S. domestic content sourcing - The company said, "Array Technologies is the front-runner in domestic content sourcing, capable of achieving in excess of 85% of content from U.S. suppliers at scale-an unparalleled benchmark in the solar industry. Array's dedication to domestic manufacturing is evidenced by its collaborations with long-standing U.S. manufacturers, bolstering its domestic content offerings. Partnering with U.S. manufacturers that have a proven track record with Array not only assures timely delivery but also minimizes potential quality risks, thus lowering risk for its valued customers."

08:40 EDT AgileThought to undergo 90-day Chapter 11 reorganization, go private - AgileThought announced additional working capital funding, a go-private transaction, and restructuring that, combined, "will reduce the company's debt load, infuse new capital into the business, and provide a firm financial foundation for its future." This transaction is underpinned by an asset purchase agreement with affiliates of Blue Torch Finance, the company's senior secured lenders, and "marks a pivotal step in AgileThought's journey towards long-term success and enhanced service delivery," the company stated. "To support the restructuring process, Blue Torch has agreed to provide approximately $22M in new-money financing (subject to court approval), which will ensure AgileThought's high-quality standards, services, and commitment to its people will remain steadfast and uninterrupted. The day-to-day operations of the company will continue seamlessly, without disruption. To ensure a smooth transition and protection for all stakeholders, AgileThought will effectuate the transaction through a 90-day Chapter 11 reorganization process under the U.S. Bankruptcy Code. This proven mechanism will allow the company to execute the transaction and efficiently reorganize its finances, reduce its debt, and emerge with a healthier balance sheet. A Blue Torch affiliate has agreed to serve as the stalking-horse buyer of substantially all of AgileThought's assets, subject to several factors, including higher or better offers. The proposed transaction is subject to court approval, and other customary conditions," the company said. Manuel Senderos, CEO of AgileThought, added, "We are excited about this transaction and what it means for our enhanced ability to deliver for our clients, people, and partners. This strategic financial reorganization will pair our already robust and thriving organization with a capital structure that matches, and this move will allow us to operate even more efficiently. Post-reorganization, we will emerge with significantly reduced debt and a private ownership structure, fortifying an even stronger and healthier AgileThought."

08:37 EDT TD enters strategic cooperation agreement with Jintongyuan - TD Holdings announced that it has entered into a strategic cooperation agreement with Shenzhen Jintongyuan Energy Storage Technology, Jintongyuan, to develop a storage battery project in southeast Asia. The Project represents the Company's ambition of stepping into the renewable energy storage battery market of southeast Asia. Pursuant to the strategic framework, both parties agree to establish a joint venture named Baiyu Energy Storage Technology in China. The Company and Jintongyuan will hold a 51% and a 49% equity interest of the JV, respectively. The Company agrees to take in charge of marketing and sales of the Project and Jintongyuan agrees to take in charge of R&D and energy storage battery production of the Project. Once completed, the anticipated annual capacity gain of the Project is expected to reach RMB 3.0 billion, approx. US$412 million, which will significantly boost the Company's gain and performance in the foreseeable future.

08:35 EDT Gorilla Mind announces partnership with The Vitamin Shop - Gorilla Mind have partnered with The Vitamin Shoppe, subsidiary of Franchise Group, to sell its newest functional energy drink in nearly 700 retail stores in the U.S. and on VitaminShoppe.com, beginning in August. As the brand expands into the fast-growing energy drinks space, it is poised to add an exciting range of flavor options to consumers nationwide, including a brand-new flavor launching exclusively at The Vitamin Shoppe.

08:34 EDT Anixa Biosciences announces treatment of third patient in CAR-T trial - Anixa Biosciences announced that, in partnership with Moffitt Cancer Center, it has commenced treatment of the third patient in the ongoing clinical trial of Anixa's novel chimeric antigen receptor T-cell, CAR-T, therapy for ovarian cancer. The study, which is being conducted at Moffitt Cancer Center, is a dose-escalation Phase 1 trial to evaluate the therapy's safety; determine the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor, FSHR; and preliminarily assess clinical activity. The third patient received the same dose of engineered T-cells as the first and second patients in the trial. Assuming safety is validated in the third patient, as was the case for the first two patients, Anixa expects to begin treatment of the second cohort in the fourth quarter of 2023. "Though enrollment of patients in this trial has been slow, which is common for clinical studies of this type, we are pleased to have completed the first cohort," stated, Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Assuming there are no safety issues with this third patient, we look forward to advancing to the next higher dose cohort."

08:33 EDT Apollo affiliates, PK Airfinance to buy $920M secured aviation loan portfolio - PK Airfinance, an aviation lending platform backed by Apollo (APO), has agreed to acquire the majority of an approximately $920 million portfolio of secured aviation loans from Standard Chartered (SCBFF), with Apollo affiliates agreeing to purchase the balance of the portfolio. The sale and transfer of the loans is subject to customary closing conditions and is expected to close year-end 2023.

08:31 EDT Tantech Holdings secures major contract to supply 50 midibuses to Malaysia - Tantech announced that its subsidiary, Shangchi Automobile, has signed a sales contract to provide midibuses to Malaysia. This is the Company's largest order from Malaysia and marks a significant stride toward enhancing public transit options and addressing the growing transportation needs in the region. This order includes 50 midibuses; each midibus measures 6 meters long and features 18 seats, with steering wheel on the right and equipped with MP5 system. "This contract marks a significant leap forward in our journey of growth and expansion. It underlines our dedication to delivering great products and services to the international markets, as well as our ability to foster strong relationships with partners across borders. " Wangfeng Yan, CEO of Tantech, commented. "The contract reflects our partners' trust in the Company's reputation for quality, innovation, and reliability. Our team's tireless efforts and unwavering commitment to exceeding customer expectations have undoubtedly contributed to the realization of this substantial achievement."

08:20 EDT Biofrontera Inc. announces results from Phase 1 safety study of BF-200 ALA - Biofrontera announces topline results from its non-randomized, open-label, multicenter Phase 1 study evaluating the safety and tolerability of 3 entire tubes of BF-200 ALA in the treatment of actinic keratosis on the face and scalp with photodynamic therapy using the RhodoLED XL lamp. Of the 100 patients treated in 9 participating clinical centers, the incidences of Treatment Emergent Adverse Events were consistent with the TEAEs listed in the US prescribing information that are based on studies with 1 tube. The treatment was generally well tolerated and TEAEs were as expected due to the therapeutic principle of photodynamic therapy. All TEAEs were transient. In most cases, they resolved within 1 to 4 days after PDT, but occasionally persisted for 1 to 2 weeks or in a few cases even longer, similar to the TEAEs observed after single-tube PDT. No Serious Adverse Events, deaths or other clinically relevant AEs were reported during the study and no subject discontinued the study due to a TEAE. With results demonstrating no additional safety or tolerability issues with 3 tubes, Biofrontera Inc. intends to present these findings to the U.S. Food and Drug Administration during the fourth quarter of this year. This Phase 1 study, conducted by Biofrontera Bioscience GmbH, follows a maximal-usage pharmacokinetics study presented to the FDA in 2021, upon which the FDA requested another safety study focusing on transient side effects before amending the product information, which currently limits use to one tube of Ameluz per treatment. Additionally, following Biofrontera Inc.'s recent announcement of completed patient enrollment in the Phase 3 clinical study evaluating Ameluz-PDT in combination with the BF-RhodoLED lamp for the treatment of basal cell carcinoma, all patients in screening at the time have now been randomized. The study is now treating 187 patients, which is one patient more than agreed upon with the FDA. The last patient to complete the final assessment, which occurs three months after their final PDT, is expected in the first quarter of 2024.

08:17 EDT Novartis presents new long-term Leqvio data - Novartis announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with twice-yearly dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol reduction beyond six years in patients with atherosclerotic cardiovascular disease, ASCVD, increased risk of ASCVD or heterozygous familial hypercholesterolemia, HeFH. The results were presented in a late-breaking session at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam. ORION-8, the largest clinical trial completed to date with Leqvio, continues to support the consistent long-term efficacy, safety, and tolerability of Leqvio, with a total exposure of more than 8,500 patient-years during the trial's three-year follow-up. Patients from four previous completed Novartis trials received Leqvio every six months for up to an additional three years. Nearly 80% of patients reached their pre-specified LDL-C targets, and on average, LDL-C levels were reduced by approximately 50%. These results demonstrate consistent efficacy as they are comparable to the LDL-C reductions observed at the end of the initial trials.

08:16 EDT Perspective Therapeutics to present data at EANM congress - Perspective Therapeutics will present new clinical and preclinical data for 212Pb-VMT-alpha-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine. The conference is being held in Vienna, Austria, from September 9-13, 2023. Presentation One: This presentation will discuss early clinical results from the study of 212Pb-VMT-alpha-NET in ten patients with somatostatin receptor-expressing progressive neuroendocrine tumors and metastatic medullary thyroid carcinomas. 212Pb-VMT-alpha-NET demonstrated an encouraging safety profile and treatment resulted in partial responses in a number of patients. Title: Early results of 212Pb-VMT-alpha-NET Targeted Alpha Therapy in Metastatic Gastro-entero-pancreatic Neuroendocrine Tumors: First in Human Clinical Experience on Safety and Efficacy. Presentation Two: This presentation will discuss the effective tumor control of fractionated doses of [212Pb]VMT-alpha-NET demonstrated in a mouse model of high-risk metastatic neuroblastoma. The data showed that fractionated doses of [212Pb]VMT-alpha-NET provided greater benefit than single dose administration of [212Pb]VMT-alpha-NET. Title: Preclinical Evaluation of [212Pb]VMT-alpha-NET Targeted Alpha Therapy for High-Risk Metastatic Neuroblastoma

08:14 EDT SaverOne 2014 launches three new international pilot projects - SaverOne 2014 announced the launch of a three new international pilot projects. The projects are all initial pilot projects on a limited number of vehicles for SaverOne's technology to prevent driver distraction from cellphones. The three projects include the heavy trucks of a fuel delivery company in the United States, the heavy trucks of a global building materials company's subsidiary in Europe and buses operating in a country in the Gulf region. "These three new international pilots for SaverOne very much demonstrate the demand and potential of the SaverOne solution globally." commented Ori Gilboa, CEO of SaverOne. "As we all know, distracted driving is a global problem, and over the coming months, we hope to effectively demonstrate the full capabilities of our technology in these new territories, as we have demonstrated in Israel, which includes reducing accidents, improving road safety and ultimately saving lives."

08:14 EDT BioVie announces three presentations from studies of NE3107 - BioVie announced details of three presentations given from studies of NE3107 in the treatment of Parkinson's Disease, or PD, at the 2023 International Congress of Parkinson's Disease and Movement Disorders, being held in Copenhagen, Denmark August 27-31. The three presentations are as follows: Effects of NE3107 Anti-Inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson's Disease in a Marmoset Monkey Model; Safety and Pharmacokinetics of Anti-Inflammatory NE3107 Treatment in Carbidopa/Levodopa-Treated; A Randomized, Phase 2a, Double-Blind, Placebo-Controlled Clinical Trial with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson's Disease.

08:12 EDT Aspira appoints Michelle Snider as SVP, commercial strategy, operations - Aspira Women's Health has named Michelle Snider as Senior Vice President, Commercial Strategy and Operations. She joins Aspira from Sema4 Genomics where she served as Vice President of Market Enablement/Sales Strategy during the company's extraordinary growth.

08:11 EDT Innovation Pharmaceuticals says BeaMed on track to file 510(k) submission - Innovation Pharmaceuticals provides shareholders with an update on recent progress in the development of BeaMed's groundbreaking StingRay Laser System. BeaMed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations. BeaMed informed the Company that it is ready to submit its family of specially designed fiber optics for FDA clearance, a key step in the development of its novel laser System for uses initially targeting the brain. Earlier, BeaMed's family of laser technologies was cleared by the FDA. The unique System is being developed to enable a perfect match between the exact structure of tumors and epileptic focal points and the energy delivery, while protecting vital functional areas against thermal damage. These features differentiate the BeaMed System from other laser-based surgical technologies. BeaMed is targeting broad therapeutic applications of the System in numerous clinical indications, including - neurosurgery, spinal surgery, urology, thoracic surgery, pulmonary surgery, gynecology, general surgery, ENT/head and neck, plastic surgery, orthopedics, arthroscopy, ophthalmology, radiology, and oral surgery. In related news, BeaMed has initiated System MRI compatibility testing at the Technion-Israel Institute of Technology, and the Rambam Health Care Campus. Integration testing is being conducted with Siemens MRI equipment, with plans to extend the testing to GE MRI equipment - two of the most common MRI device manufacturers worldwide. Additionally, sessions with Key Opinion Leaders in the neurosurgery field generated excitement about the System's potential to improve treatment of epilepsy and brain cancer. BeaMed is on track to submit, in Q2 2024, the System for potential FDA approval via the 510(k) regulatory pathway. BeaMed's other shareholders are the controlling shareholders of neoLaser, now the industry leader in their class of lasers in some European and Asian markets.

08:10 EDT Elicio appoints Megan Filoon as General Counsel - Elicio Therapeutics announced the appointment of Megan Filoon as General Counsel and Thian Kheoh as Senior Vice President of Biometrics. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company's product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002. Megan Filoon most recently served as the General Counsel and Corporate Secretary for Molecular Templates, a publicly traded, oncology-focused biotech, where she was responsible for providing legal counsel to the company's board of directors and management team and advising on corporate governance, securities, employment, and real estate matters, among other areas. In this role, Filoon was responsible for managing the legal, human resources and administrative departments. Thian Kheoh,has over 30 years of drug development and clinical trial experience in the biopharmaceutical industry. He most recently served as Vice President of Biometrics at Mirati Therapeutics where he led the Biometrics team in obtaining the FDA approval of KRAZATI for KRAS G12C NSCLC patients.

08:09 EDT Hyundai Motor, Autotalks collaborate to implement V2X technology for cars - Hyundai Mobis and Autotalks are set to unveil their latest joint effort: Hyundai Mobis' MTCU, Multi-functional Telematics Control Unit, connectivity modules. MTCU Gen1, Hyundai Mobis' most advanced connectivity module to date, supports Day-1 V2X services in all geographies. Powered by Autotalks' V2X chipset, the MTCU Gen1 sets the standard for high-performance, globally compatible automotive V2X. As the demand for V2X continues to grow, primarily driven by the global NCAP roadmap, Hyundai Mobis selected Autotalks' 3rd generation chipset to power its next-generation connectivity module solution, MTCU Gen2. The MTCU Gen1 module will be showcased at the upcoming IAA Mobility exhibition, which will take place in Munich, Germany, between September 5th and September 10th, 2023.

08:08 EDT Ree Automotive partners with Knapheide to create EV solutions - REE Automotive is working in partnership with Knapheide to create full electric vehicle solutions. Knapheide will upfit REE's P7-C chassis cabs to meet the requirements for fleet customers across all electric vehicle types ranging from Class 3-5. Knapheide bodies will complete REE's chassis cab built as part of their flagship P7 electric truck lineup. The P7-C chassis cab was built to encourage flexibility and customization to fit the needs for a range of customer applications. The electric vehicles are powered by the REEcorners, x-by-wire technology and are purpose-built to drive down total cost of ownership for fleets. The vehicles are built for urban environments with market-leading product attributes including optimal maneuverability, full height interior cabs, class-exclusive all wheel drive, low step-in height, aerodynamic design, low noise, greater visibility and increased safety. All P7 configurations with Knapheide bodies including box trucks, service bodies and platform bodies are currently available to order with initial deliveries expected in 2024.

08:07 EDT CPI Aerostructures awarded contract by Lockheed Martin - CPI Aerostructures (CVU) announced that it has been awarded a second multi-year contract by Lockheed Martin (LMT) to manufacture structural assemblies for the most advanced F-16 ever produced - the F-16 Block 70/72. Under the terms of the contract with Lockheed Martin, CPI Aero will provide Rudder Island and Drag Chute Canister, or RI/DCC, assemblies for the F-16. The RI/DCC is a large structural sub-assembly installed under the vertical tail section of the aircraft. Deliveries are expected to begin in 2025 and continue through 2028.

08:06 EDT Bath & Body Works to begin hiring seasonal holiday associates - Bath & Body Works will begin hiring seasonal associates both in-store and at their distribution centers for the 2023 holiday season. Applications go live on August 29, 2023. Stores across the United States, Canada and Puerto Rico are opening their doors to 30,000 seasonal holiday sales associates. For holiday sales associates, candidates have until October 22, 2023 to apply. For some positions, there are opportunities to transition to long-term employees. Outside of opportunities for longer-term employment, Bath & Body Works holiday store associates are eligible for a comprehensive set of benefits. Associates receive flexible schedules and a 40% store-wide discount. Bath & Body Works will also host two National Hiring Events across all stores on Saturday, 9/23 and Thursday, 10/12. Prospective applicants can go to their local store for an interview and offers will be given immediately to qualified candidates. Bath & Body Works is also looking to hire around 2,500 distribution center employees across four central Ohio distribution centers. Benefits include a competitive wage - ranging from $18.25 to $23.50 hourly, flexible work schedule and a 40% store-wide discount. For some positions, there are opportunities to transition to long-term employment. Candidates have until mid-December to apply, and there's a $500 associate referral bonus program.

08:05 EDT USPTO issues patent for Enveric's lead candidate EB-373 to treat anxiety - Enveric Biosciences announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,707,441, titled "C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using," pertaining to the Company's lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder. This new patent, issued July 25 provides Enveric with intellectual property rights for compositions and methods for tryptamine-derived prodrugs utilizing C4-substituted tryptamine derivatives and C4-carbonothiate-substituted tryptamine derivatives. These enhancements to the tryptamine chemical structure are designed to potentially elicit a more rapid onset of action, more controlled therapeutic effect, and reduced gastrointestinal side-effects compared to conventional psilocin prodrugs, such as psilocybin. Enveric's lead product candidate, EB-373, is a new chemical entity NCE psilocin prodrug being developed for the treatment of anxiety disorder. "This U.S. patent issuance is a significant milestone for Enveric in our effort to advance novel tryptaminecompounds that are unique and differentiated from other psilocin-based candidates being developed for the treatment of mental health disorders," said Joseph Tucker, Ph.D., Director and CEO of Enveric. "Several tryptamines including psilocybin, DMT and 5MeO-DMT have shown therapeutic benefit for the treatment of numerous psychiatric diseases. However, these compounds are not optimized for induction of consistent and predictable neuroplasticity, resulting in intense psychedelic experiences that are a barrier to widespread therapeutic application. With EB-373 and our EVM201 and EVM301 Series, we are focused on creating innovative, non-obvious alterations to related compounds that are intended to generate neuroplastic changes which will yield efficacious treatments for critical mental health disorders, while also minimizing unwanted side effects and safety concerns." "Enhancing the IP protection for our technologies is a key growth driver for Enveric, and we have recently received multiple notices of allowance from the USPTO for EB-373 and our EVM201 and EVM301 Series. We now anticipate several of these applications to result in U.S. patents over the coming months," said Tucker.

08:05 EDT Thorne HealthTech to be acquired by L Catterton for $10.20 per share in cash - Thorne HealthTech announced that it has entered into a definitive agreement under which L Catterton will commence a tender offer to acquire all outstanding shares of common stock of Thorne for $10.20 per share in cash. The transaction value of approximately $680M represents a 94% premium to the unaffected closing share price on July 20, 2023, and a 113% premium to the 30-day volume weighted average price as of the unaffected date of July 20, 2023. Thorne's independent Special Committee and Board of Directors have each unanimously approved the agreement and recommend that all stockholders tender their shares in the tender offer. Under the terms of the agreement, which was unanimously approved by Thorne's independent Special Committee and Board of Directors, L Catterton will commence a tender offer to acquire all of Thorne's outstanding shares of common stock for $10.20 per share in cash. The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions, including satisfaction of the minimum tender condition and receipt of regulatory approvals. Subject to the terms and conditions of the agreement, following the completion of the tender offer, L Catterton will acquire any shares of Thorne that are not tendered in the tender offer through a second-step merger for $10.20 per share in cash. Upon completion of the transaction, Thorne will become a privately held company and its shares of common stock will no longer be listed on any public market.

08:03 EDT Aemetis appoints Michael Rockett as Executive Vice President - Aemetis has appointed J. Michael Rockett as Executive Vice President, General Counsel and Corporate Secretary, effective immediately. Rockett brings over 28 years of relevant experience to the company. Prior to joining Aemetis, he was Vice President, General Counsel, and Corporate Secretary of InEnTec, a developer of technology and facilities to convert waste into renewable fuels and chemical products. Rockett was formerly an attorney at the law firm of Pillsbury Winthrop Shaw Pittman in San Francisco, and a Trial Attorney in the Environment and Natural Resources Division of the United States Department of Justice in Washington D.C. and San Francisco. He obtained his law degree, magna cum laude, from Lewis and Clark College and a Bachelor of Arts in Economics from Dartmouth College. Between college and law school, Mr. Rockett worked as an economist at a consulting firm providing services to energy companies.

07:55 EDT Nano Dimension says ISS recommends shareholders vote for all nominees - Nano Dimension announced that Institutional Shareholder Services has recommended that Nano Dimension shareholders vote in "FOR" Nano Dimension's nominees and AGAINST ALL MURCHINSON NOMINEES at the upcoming Annual General Meeting of Shareholders, scheduled for Thursday, September 7th, 2023. In its recommendation that shareholders vote FOR Nano Dimension's nominees who are up for election, ISS noted: "NNDM has meaningfully outperformed its 3D printing peers over Stern's tenure as CEO" since January 2020 "and continues to execute on its stated strategy to grow the top- line and pursue acquisitions to build out its platform...The company and Stern deserve credit for capitalizing on a favorable financing environment in 2020 and 2021. The company also appears to be executing on its strategic plan, as it continues to show double digit top-line revenue growth, expanding gross margins... NNDM has posted steady top-line growth since 2020 and through Q2 2023, while also expanding gross margins. The company appears to also have begun to drive organic revenue growth through Q2 2023, a sign that its M&A strategy to drive continued revenue growth from its acquisitions may be starting to come to fruition....The company maintains almost $1 billion in cash on the balance sheet and is continuing to pursue acquisitions to build out its 3D printing and additive manufacturing capabilities in-step with its stated long-term strategy."In its recommendation that shareholders vote AGAINST the Murchinson nominees, ISS stated: "Support for the three dissident nominees is not warranted, as the dissident has not made a sufficiently compelling case for board control...The dissident has not presented any specific details of a potential plan, whether it be cost cutting, divestments of specific business segments, or identification of areas that may require additional investment...the plan as presented does not indicate a deep experience with the 3D printing industry or a view on what the company's operational issues may be at this time...The dissident case for control falls short in several key areas, including the lack of an identified leadership team or a detailed go-forward plan, as well as a dissident slate that does not appear to have direct 3D printing industry expertise."

07:41 EDT Pipestone Energy, Strathcona Resources announce receipt of interim order - Pipestone Energy and Strathcona Resources jointly announced that Pipestone and Strathcona obtained an interim order of the Court of King's Bench on August 25, 2023 and Pipestone has filed a management information circular dated August 25, 2023 and related meeting and proxy materials in connection with the proposed arrangement under the Business Corporations Act which provides for, among other matters, the acquisition by Strathcona of all of the issued and outstanding common shares of Pipestone pursuant to the arrangement agreement between Pipestone and Strathcona dated effective July 31, 2023.

07:38 EDT Superluminal Medicines closes $33M seed round - Superluminal Medicines announced the closing of a $33M funding round. The investment was led by RA Capital Management with significant participation from Insight Partners and NVIDIA. Gaingels also joined in the financing. The funding will be used to progress Superluminal's pipeline of small molecule drug discovery programs initially focused on high-value G protein-coupled receptor targets. The company's pipeline stems from its platform, which creates candidate-ready compounds with differentiated TPPs in just months by utilizing a unique combination of human understanding, generative biology and chemistry, machine learning, and proprietary big data infrastructure.

07:34 EDT Danaher enters agreement to acquire Abcam for $24 per share in cash - Danaher (DHR) announced that it has entered into a definitive agreement to acquire Abcam (ABCM) pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion including assumed indebtedness and net of acquired cash. Abcam is expected to operate as a standalone operating company and brand within Danaher's Life Sciences segment, furthering Danaher's strategy to help map complex diseases and accelerate the drug discovery process. Rainer Blair, President and Chief Executive Officer, Danaher, said: "We couldn't be more excited to have Abcam join Danaher. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio positions them as a key partner for the scientific community. We look forward to welcoming Abcam's innovative and talented team to Danaher as we continue to help our customers solve some of the world's biggest healthcare challenges." The transaction is anticipated to close mid-2024 and is subject to customary conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval.

07:33 EDT Hersha Hospitality and KSL announce definitive merger agreement - Hersha Hospitality Trust and KSL Capital Partners, a leading investor in travel and leisure businesses, announced a definitive merger agreement, entered into on August 27, under which affiliates of KSL will acquire all of the outstanding common shares of Hersha for $10.00 per share in an all-cash transaction valued at approximately $1.4B. The purchase price represents a premium of approximately 60% over Hersha's closing share price on August 25, the last full trading day prior to this announcement. Under the terms of the merger agreement, which has been unanimously recommended by the independent Transaction Committee of Hersha's Board of Trustees and unanimously approved by Hersha's full Board of Trustees, Hersha shareholders will receive $10.00 in cash for each common share they own, and holders of Hersha's 6.875% Series C Cumulative Redeemable Preferred Shares, 6.50% Series D Cumulative Redeemable Preferred Shares and 6.50% Series E Cumulative Redeemable Preferred Shares will receive $25.00 in cash, plus any accrued and unpaid dividends to which they are entitled, for each preferred share they own. The transaction is expected to close in the Q4. Goldman Sachs & Co. is serving as exclusive financial advisor and Latham and Watkins and Venable are serving as legal advisors to the Transaction Committee of Hersha's Board of Trustees. Hunton Andrews Kurth is serving as legal advisor to Hersha. Wells Fargo and Citigroup are serving as financial advisors and Simpson Thacher & Bartlett and Miles and Stockbridge P.C. are serving as legal advisors to KSL. Additionally, Wells Fargo and Citigroup provided a debt financing commitment to KSL in connection with the transaction.

07:32 EDT LEXEO Therapeutics announces strategic investment from Sarepta - LEXEO Therapeutics announced a strategic investment from Sarepta Therapeutics to support the advancement of LEXEO's adeno-associated virus gene therapy programs. In connection with this investment, the companies will explore the development of novel gene therapy candidates for a range of cardiovascular diseases. Financial details of the investment were not disclosed.

07:14 EDT Hot Chili signs binding letter of intent for option to acquire Cometa Project - Hot Chili announce that the Company has entered into a binding letter of intent, LOI, with Bastion Minerals for the grant to Hot Chili of an option to acquire 100% of Bastion's Cometa Project in Chile, located near Hot Chili's Costa Fuego Copper-Gold Project in the coastal range of the Atacama Region, Chile. Cometa consists of exploration and mining concessions covering approximately 56km2 in area located approximately 15km southeast of Costa Fuego's planned operating centre and contiguous with Hot Chili's landholdings in the region. The option is another step in Hot Chili's consolidation strategy for the Costa Fuego copper project. The material terms of the LOI are as follows: Exclusivity period of 60 days for Hot Chili to conduct due diligence and for Hot Chili's subsidiary Sociedad Minera La Frontera SpA to enter into a definitive option agreement with Bastion's subsidiary SCM Cornet Constelacion. Non-refundable cash payment of US$100,000 to Bastion upon grant of the Option. Non-refundable cash payment of US$200,000 within 12 months from the grant of the Option to keep the Option in good standing. Option may be exercised within 30 months of the date of grant. If the Option is exercised, the consideration payable to Bastion to purchase the Cometa concessions is: US$2,400,000 if the Option is exercised by Hot Chili within 18 months from the date of grant of the Option; or US$3,000,000 if the Option is exercised by Hot Chili within 30 months from the date of grant of the Option. Hot Chili may elect to satisfy the purchase consideration in cash, or in cash and ordinary shares of Hot Chili issued at a price per share equal to the 15-day VWAP at the date of exercise of the Option, subject to applicable regulatory approvals, including the approval of the TSX Venture Exchange.

07:12 EDT Garmin smartwatches help U.S. Space Force fitness study - Garmin smartwatches are being deployed by the thousands to help assess the physical fitness of U.S. Space Force Guardians, the company announced. Commissioned by the Air Force Research Laboratory, AFRL, the two-year study will explore the effectiveness of smartwatch technology to supplant annual physical fitness assessments. Guardians who actively participate in the study will be exempt from U.S. Air Force physical fitness assessments. Enrollment has been robust, with over two-thirds of the 8,400-strong Space Force signing up since the program was announced in May. Garmin Instinct 2 Solar and Forerunner 55 smartwatches were chosen for the U.S. Space Force's Continuous Fitness Assessment project because they offer abundant battery life, high-quality biometric data and the ability to disable GPS functionality.

07:10 EDT Tecnoglass expands into vinyl window market - Tecnoglass announced its entry into the vinyl window market. This expansion more than doubles the Company's addressable market and is expected to further solidify its position as an industry leader in architectural windows and glass solutions. The decision to enter the vinyl window market is directly aligned with Tecnoglass' ongoing diversification strategy to expand its footprint and leverage its competitive advantages. The Company has signed a long-term supply agreement to procure vinyl frame profiles from a premier global manufacturer. Given its comprehensive vertically integrated manufacturing platform and its growing network of dealers and distributors, many of which already sell vinyl products, the Company expects to start production and deliveries in November, more than doubling its addressable market while increasingly diversifying its revenue base going forward.

07:08 EDT Medicenna Therapeutics appoints Jeff Caravella as CFO - Medicenna Therapeutics (MDNA) announced the appointment of Jeff Caravella as CFO. In this position, Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointment underscores the Company's commitment to expanding its operations in Boston and follows the recent appointment of Brent Meadows as Chief Business Officer. Caravella brings to Medicenna over 20 years of global healthcare, financial and operational experience. Most recently, he served as CFO at Biotheryx, where he led the finance, investor relations and operational functions and supported activities associated with an up to approximately $350M collaboration with Incyte. Prior to Biotheryx, he served as Vice President of Finance at Tango Therapeutics (TNGX), where he built and led the finance and accounting functions, successfully supported approximately $110M in private financings and an approximately $350M SPAC and PIPE transaction. Previously, Jeff held senior finance roles at Editas Medicine (EDIT), Charles River Laboratories and Johnson & Johnson (JNJ).

07:06 EDT Ashland changes start time for 2023 Innovation Day - Ashland has changed the start time of the company's Innovation Day being held on Tuesday, September 12, 2023. The event will now begin at 9:30 a.m. ET instead of 9:00 a.m. ET for both in-person attendees as well as those participating by webcast.

07:05 EDT Canoo names Ehtridge Chief Financial Officer - Canoo announced it has named current Board Member Greg Ethridge as Chief Financial Officer, succeeding Ken Manget. Ethridge will report to Canoo Chairman and CEO, Tony Aquila. This move is effective immediately, and Ethridge will assume responsibilities for capital markets, investor relations, accounting & financial reporting functions. Ethridge agrees to resign from Canoo's Board of Directors by the end of the year. Ethridge eviously served as president, chief operating officer and a director of Hennessy Capital Acquisition Corporation IV, V and VI.

07:04 EDT Genelux appoints Lourie Zak as CFO - Genelux announced that Lourie S. Zak will join the company as CFO, effective August 28. Zak will join Genelux with an extensive background in CFO roles, including Guitar Center Brands, Sonifi Solutions, and PBS Biotech. Zak started her biotech career at Amgen where she progressively moved into more senior positions, including Executive Director Finance, Global Commercial Operations. Zak brings years of accounting and financial management expertise to her role at Genelux as the company continues to execute its operating plan, which includes building a commercially ready team and supporting the potential launch of Olvi-Vec. Doug Samuelson, who played an important role as the Company's CFO during its IPO earlier this year, is set to resume his position as Vice President of Finance.

07:03 EDT Orthofix announces first case, commercial launch of 7D Flash - Orthofix announced the full commercial launch and completion of the first cases in the U.S. with the 7D Flash Navigation System Percutaneous Module 2.0. The Percutaneous Module 2.0 provides new planning features and increased functionality for the 7D Flash Navigation System.

07:02 EDT Gain Therapeutics announces preclinical data from drug candidate GT-02287 - Gain Therapeutics announced preclinical data demonstrating the Company's lead drug candidate GT-02287 significantly decreased Parkinson's disease, or PD,-associated pathology and improved motor dysfunction in two different preclinical models of Parkinson's disease. Of note, GT-02287 significantly reduced plasma Neurofilament Light Chain, or NfL, levels, an emerging biomarker for neurodegeneration, in a mouse model of GBA1-PD. The findings are being presented in two posters, including one that was accepted as a late breaking abstract, at the International Congress of Parkinson's Disease and Movement Disorders being held in Copenhagen, Denmark from August 27-31. The first poster titled "Neuroprotective effect of GT-02287, a brain-penetrant structurally targeted allosteric regulator of glucocerebrosidase, leads to a significant reduction of plasma NfL levels and improvement in behavioural deficits in a mouse model of GBA1 Parkinson's disease" will be presented by Dr. Taylor. Researchers used a mouse model of GBA1-PD, created using conduritol beta epoxide (CBE) to induce GCase deficit comparable to GBA1-PD. Oral administration of GT-02287 over 14 days significantly reduced aggregated alpha-synuclein, neuroinflammation and neuronal death in the brain. Treatment with GT-02287 also increased tyrosine hydroxylase immunostaining, a marker of dopaminergic neurons, as well as dopamine levels, and improved motor strength and motor coordination.

06:52 EDT Virgin Galactic announces flight window for third commercial spaceflight - Virgin Galactic announced the 'Galactic 03' flight window will open September 8, 2023, continuing a monthly cadence of spaceflights. This would be the Company's fourth spaceflight in four months. The three 'Galactic 03' crew members are the first of Virgin Galactic's group of 'Founder' astronauts - the first customers whose forward-thinking vision and early ticket purchases helped make the dream of regular commercial spaceflights a reality. The pilots for 'Galactic 03' are VSS Unity Commander, Nicola Pecile, and VSS Unity Pilot, Michael Masucci; the Astronaut Instructor is Colin Bennett. In the past twelve weeks, Virgin Galactic has introduced eleven new astronauts to the world. Following the 'Galactic 03' spaceflight, the customers on board would become Virgin Galactic astronauts 014, 015 and 016.

06:45 EDT Fortescue Metals CEO Fiona Hick departs, Dino Ortranto to succeed - Fortescue Metals Group advises that the Board has decided to expedite the appointment of Dino Otranto as CEO of Fortescue Metals. Further, the company announced Dr Larry Marshall as a Non-Executive Director of Fortescue to guide the Company's overall technology pathway, particularly in energy, metals, investments and strategy. Since joining Fortescue in 2021 as COO Iron Ore, Dino has become an integral member of the Fortescue family. Fiona Hick has made a joint decision with the Fortescue Board to leave the company. The company said, "The departure of Fiona has been both friendly and mutual and we warmly wish her the best for her future." Dino will lead Fortescue Metals and Mark Hutchinson will lead Fortescue Energy. Both Leaders will report to the Executive Chairman and the Fortescue Board. Reference Link

06:38 EDT Ault Inc. announces BitNile.com will launch Blackjack on its platform - Ault Alliance (AULT) announced that the metaverse platform, BitNile.com, will be expanding its social gaming experience with the launch of Blackjack expected on September 1, 2023. The Platform is owned and operated by BitNile.com, a wholly owned subsidiary of BitNile Metaverse (BNMV), which is a consolidated minority beneficially owned subsidiary of Ault Alliance. BNC believes that the popular casino game will increase revenue from the sale of in-world coins that are required to play its new and exciting Blackjack sweepstakes-based game. "We are very pleased that the Platform will be launching Blackjack as a part of its social gaming experience. I am excited to see the team at BNC harnessing its potential to generate significant revenue. More importantly, this new addition underscores BNC's commitment to deliver a rich, engaging metaverse experience. While it's still early in the ramp-up cycle, there is tremendous potential for future growth. There is a world of opportunities yet to be explored," stated Milton Ault, III, Executive Chairman of the Company and BNC.

06:34 EDT Centrus Energy and Oklo sign MOU - Oklo and Centrus Energy announced a new Memorandum of Understanding, or MOU, between the two companies to support the deployment of Oklo's advanced fission powerhouses and advanced nuclear fuel production in Southern Ohio, making the region a critical hub for the future of the U.S. nuclear industry. With this new MOU, Oklo and Centrus plan to enter into a broad range of collaboration programs supporting the development and operation of Oklo's Aurora powerhouses including supply of HALEU produced by Centrus at its Piketon, Ohio, facility. Centrus also intends to buy clean, reliable, and affordable energy from Oklo's planned Ohio plants to power its HALEU Production Facility. The parties intend to enter into one or more definitive agreements relating to the following collaborative activities addressed in the MOU: Oklo would purchase HALEU from the production facility Centrus is planning to build in Piketon, Ohio, the only such facility licensed by the U.S. Nuclear Regulatory Commission to produce HALEU. Centrus would purchase electricity from the Aurora powerhouses that Oklo is planning to build in Piketon. Centrus would manufacture components for Oklo's Aurora powerhouse at Centrus' advanced manufacturing facility in Oak Ridge, Tennessee, as well as manufacturing capacity at the American Centrifuge Plant in Piketon, Ohio, where HALEU production will take place. Centrus and Oklo would work together to establish and license the capabilities necessary to deconvert HALEU from uranium hexafluoride to uranium metal and fabricate fuel assemblies for Oklo's Aurora powerhouses.

06:32 EDT ImmunoGen announces collaboration with Takeda for ELAHERE - ImmunoGen (IMGN) announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited (TAK) to develop and commercialize ELAHERE in Japan. "As a leader in the development and commercialization of novel products in oncology for more than two decades and with a deep heritage and presence in Japan, Takeda is the ideal partner to help us deliver ELAHERE to eligible patients in this important market," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "Building upon our strong commercial launch in the US, this partnership reinforces the continued excitement around ELAHERE's practice-changing potential and our commitment to bringing this biomarker-directed ADC to patients globally." Under the terms of the collaboration and license agreement, ImmunoGen will receive a one-time, upfront payment and an additional payment upon conversion of US Food and Drug Administration accelerated approval of ELAHERE in platinum-resistant ovarian cancer to full approval. The Company is eligible to receive additional payments if Takeda achieves prespecified regulatory and commercial milestones, as well as double-digit royalties on future net sales of ELAHERE in Japan. Per the agreement, ImmunoGen has retained exclusive production rights and will supply product for development and commercial use in Japan. In exchange, Takeda will receive an exclusive license to develop and commercialize ELAHERE in Japan and is responsible for all regulatory filings and obligations.

06:21 EDT United Rentals announces departure of COO Asplund, Durand to succeed - United Rentals announced that Dale Asplund, executive vice president and chief operating officer, COO, will be leaving the company on September 29, 2023, to take the role of president and chief executive officer at another public company outside of the equipment rental industry. Asplund joined United Rentals in 1998 and was named chief operating officer in 2019. He will remain in an active role with United Rentals through September 29 to ensure a smooth transition to Michael Durand, who is being promoted to chief operating officer.

06:18 EDT BrightView appoints Asplund as President, CEO - BrightView Holdings (BV) announced that its Board of Directors has appointed Dale Asplund as President and Chief Executive Officer, effective October 1, 2023. In conjunction with his appointment as CEO, Asplund will also join the BrightView board as a director as of that date. Asplund succeeds Interim President and CEO Jim Abrahamson. Abrahamson, who has served as a BrightView independent director since 2015, will remain as a member of the Board. Asplund brings 25 years of expertise to BrightView from United Rentals (URI), where he was most recently Executive Vice President and Chief Operating Officer.

06:05 EDT Insulet announces full market release of Omnipod 5 in Germany - Insulet Corporation announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes in its third market, Germany. Omnipod 5 is also available in the U.S. and the U.K. "We know people in Germany living with type 1 diabetes want the most advanced technology options for making diabetes management easier," said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director. "With our impressive data showing improved clinical outcomes from users in the United States over the past year, we are confident in our ability to make a difference in Germany and additional markets in the near future." Omnipod 5 is the first CE marked tubeless automated insulin delivery system that integrates with the Dexcom G6 Continuous Glucose Monitoring System. The Company's goal is to make Omnipod 5 available for the majority of Insulet's European customers by the end of 2024.

06:03 EDT XPeng rallies 4% to $18.30 after announcing DiDi partnership

06:02 EDT Verisk, Plaintar announce strategic integration to accelerate claims process - Planitar and Verisk announced a strategic integration aimed at accelerating the insurance industry's claims process. Leveraging the market-leading technology of both providers, the collaboration introduces a solution, iGUIDE Instant Sketch. This integration of iGUIDE and Verisk's Xactimate platform is designed to enable insurance adjusters to process claims with accuracy, speed and increased efficiency. "Our collaboration with Planitar brings an unparalleled opportunity for insurance adjusters to leverage technology from our ecosystem partners together with the power of the Xactimate claims processing platform. Together, we're working to simplify the claims Sketch process, improve the quality of loss documentation and enhance adjusters' productivity," explained Aaron Brunko, president, Property Estimating Solutions, Verisk.

05:58 EDT Boston Scientific announces AVENT study met primary, safety endpoints - Boston Scientific announced 12-month results from the pivotal ADVENT clinical trial of the Farapulse Pulsed Field Ablation, or PFA, System, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation, or AF. The study is the first randomized clinical trial to directly compare the efficacy and safety of the Farapulse PFA System against standard-of-care ablation - either radiofrequency or cryoablation - for the treatment of patients with paroxysmal, or intermittent, AF. Findings were presented at ESC Congress 2023, the annual meeting of the European Society of Cardiology, and simultaneously published in The New England Journal of Medicine. Data demonstrated the Farapulse PFA System was noninferior to standard-of-care therapies, meeting the primary efficacy and safety endpoints, despite the vast majority of physicians having prior experience solely with thermal ablation. Through 12 months, the single-procedure, off-drug treatment success was 73.3% in the PFA arm of the study and 71.3% in the thermal arm, which met the primary efficacy endpoint. The primary composite safety endpoint - defined as acute and chronic device- and procedure-related serious adverse events within seven days of the procedure - was met with a comparably low adverse event rate of 2.1% in the PFA arm and 1.5% in the thermal arm. Results demonstrated superiority of the Farapulse PFA System in the study's secondary safety endpoint with significantly less post-ablation narrowing of the pulmonary veins at three months compared to the thermal ablation arm. There were statistically shorter ablation times and less variability with the Farapulse PFA System within the PFA arm of the study compared to the thermal arm. In this multicenter, prospective and randomized controlled trial, 607 patients in the U.S. with paroxysmal AF who had previously been unsuccessfully treated with at least one anti-arrhythmic drug were enrolled.

05:17 EDT Hawaiian Electric issues update on Lahaina fires, in response to lawsuit - Hawaiian Electric issued the following update in response to the lawsuit filed on Thursday by the County of Maui. A fire at 6:30 a.m. appears to have been caused by power lines that fell in high winds. The Maui County Fire Department responded to this fire, reported it was "100% contained," left the scene and later declared it had been "extinguished." At about 3 p.m., a time when all of Hawaiian Electric's power lines in West Maui had been de-energized for more than six hours, a second fire began in the same area. The cause of the devastating Afternoon Fire has not been determined.

05:07 EDT Verisk Analytics enters Egypt health insurance market through AXA deal - AXA Life & Health Reinsurance Solutions has selected Verisk's Health Risk Rating Tool and Ratings Engine to help its insurance partners in Egypt automate health insurance underwriting based on the declared pre-existing medical conditions of their customers. This deal marks the first time Verisk, a global data analytics and technology provider for insurers, provides a product or service to Egypt's insurance market. Verisk's Health Risk Rating Tool, which will be marketed as AXA's Intelligent Medical Acceptance Tool, or IMPACT, enables insurers to grow by helping them make more informed underwriting decisions at point of sale. The solution analyses an applicant's responses to a dynamic question set, assesses the applicant's pre-existing medical conditions, and generates risk scores that insurers can use to better understand the cost of maintaining a condition and any potential complications. Verisk's Health Risk Ratings Engine is an additional module of the solution that streamlines the process by allowing insurers to configure their own rules based on the risk scores and generate real-time automated underwriting decisions. This deal builds on an existing business relationship between Verisk and AXA Life & Health Reinsurance, with AXA using Verisk's Health Risk Rating Tool in China, Vietnam and the Philippines.